Table 6.

Alternative scenario analyses: cost-effectiveness results for secukinumab vs other biologics by varying base-case assumptions

Parameters	Base case	Scenarios tested	Results
Population	Biologic naïve	Biologic-naïve and biologic- experienced population	Similar to base casea
Utility	MEASURE 1 and 2 trial data	McLeod et al (2007)33	Similar to base casea
Disutility	Not included	Included	Similar to base casea
BASFI rebound assumptionb	Natural history	Initial gain	Similar to base casea
Indirect costs	Not included	Included	Secukinumab dominates all branded biologics and was cost-effective against biosimilars
Disease-specific costs	Included	Excluded	Similar to base casea

Notes:

^aSimilar to base-case results, means secukinumab 150 mg dominates all its comparator with higher QALYs and lower costs.

^bBASFI can be assumed to deteriorate in two ways: 1) rebound equal to gain: BASFI deteriorates by the same amount by which it improved when they responded to therapy; 2) rebound back to natural history: BASFI deteriorates to the level and subsequent trajectory it would have been had they not initially responded to therapy. Detailed results for all scenarios are available in supplementary materials (Tables S12–S17).

Abbreviations: BASFI, Bath Ankylosing Spondylitis Functional Index; QALYs, quality-adjusted life years.